Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer

已完结 10 由达姆发布于 2026/2/24 14:49:46

DOI:10.1001/jamaoncol.2025.6585
作者：Noor Wortelboer, Annemiek van Ommen-Nijhof, Inge R. Konings, Vincent van der Noort, Esther van den Pol, Cristina Guerrero Páez, Sandra D. Bakker, Sjoerd Hovenga, Alex L. T. Imholz, Yvonne J. L. Kamm,
文献类型：期刊论文
补充材料：只需要正文

JAMA

Abstract：Importance Cyclin-dependent kinase (CDK) 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are widely used in hormone receptor (HR)–positive, ERBB2 -negative advanced breast cance

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:JAMALessons From the SONIA Trial on Timing of CDK4/6 Inhibitors in Advanced Breast Cancer-The Sooner, the Better?